Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dna X (SONM) Common Equity (2018 - 2025)

Dna X (SONM) has disclosed Common Equity for 8 consecutive years, with -$701000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Common Equity fell 104.57% year-over-year to -$701000.0, compared with a TTM value of -$701000.0 through Sep 2025, down 104.57%, and an annual FY2024 reading of -$5.7 million, down 125.48% over the prior year.
  • Common Equity was -$701000.0 for Q3 2025 at Dna X, up from -$1.3 million in the prior quarter.
  • Across five years, Common Equity topped out at $23.1 million in Q3 2023 and bottomed at -$5.7 million in Q4 2024.
  • Average Common Equity over 5 years is $13.4 million, with a median of $17.5 million recorded in 2024.
  • The sharpest move saw Common Equity surged 208.74% in 2023, then crashed 125.48% in 2024.
  • Year by year, Common Equity stood at $18.6 million in 2021, then grew by 7.6% to $20.0 million in 2022, then grew by 11.59% to $22.4 million in 2023, then plummeted by 125.48% to -$5.7 million in 2024, then soared by 87.7% to -$701000.0 in 2025.
  • Business Quant data shows Common Equity for SONM at -$701000.0 in Q3 2025, -$1.3 million in Q2 2025, and -$1.1 million in Q1 2025.